Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer

Published:2022-09 Issue:3 Volume:21 Page:229-235
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Punt Cornelis J.A.,Kwakman Johannes J.M.,Mol Linda,Roodhart Jeanine,Hendriks Mathijs,Speetjens Frank,van Iersel Liselot,Trajkovic-Vidakovic Marija,Spierings Leontine,Helgason Helgi,Creemers Geert-Jan,de Groot Jan Willem,van Dodewaard-de Jong Joyce,Los Maartje,Koornstra Rutger,Baars Arnold,Koopman Miriam,Vink Geraldine

Funder

Nordic Pharma Group

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference19 articles.

1. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients;Schüller;Cancer Chemother Pharmacol,2000

2. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators;Shirasaka;Anticancer Drugs,1996

3. Oral drugs in the treatment of metastatic colorectal cancer;Kwakman;Expert Opinion Pharmacother,2016

4. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch colorectal cancer group;Kwakman;Ann Oncol,2017

5. Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm;Kwakman;Eur J Cancer,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study);Acta Oncologica;2024-05-02

2. Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?;Current Treatment Options in Oncology;2024-02-17

3. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer;ESMO Open;2023-04

4. Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis;International Journal of Colorectal Disease;2023-03-06

5. Multiple drugs;Reactions Weekly;2022-10-15